2. Immunology/Inflammation Metabolic Enzyme/Protease
  3. Interleukin Related Endogenous Metabolite
  4. Lipoxin A4

Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Lipoxin A4

Lipoxin A4 Estructura química

No. CAS : 89663-86-5

Tamaño Precio Stock Cantidad
Solvent
25 μg (283.71 μM * 250 μL in Ethanol) En stock

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 publication(s) in Google Scholar

Other Forms of Lipoxin A4:

Lipoxin A4 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Lipoxin A4

Ver todos los productos específicos de isoformas Interleukin Related:

Ver todas las isoformas
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Ver todos los productos específicos de isoformas Endogenous Metabolite:

Ver todas las isoformas
Human Endogenous Metabolite Microbial Metabolite

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

IC50 & Target

IL-6

 

IL-8

 

Human Endogenous Metabolite

 

Cellular Effect
Cell Line Type Value Description References
THP-1 EC50
5 nM
Compound: 1
Induction of phagocytosis in human THP-1-MF0 macrophages pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
Induction of phagocytosis in human THP-1-MF0 macrophages pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
[PMID: 34138563]
THP-1 IC50
1 pM
Compound: 1
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IFNgamma release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IFNgamma release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
[PMID: 34138563]
THP-1 IC50
1 pM
Compound: 1
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-1beta release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-1beta release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
[PMID: 34138563]
THP-1 IC50
1 pM
Compound: 1
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-6 release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-6 release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
[PMID: 34138563]
In Vitro

LXA4 pretreatment (100 nM for 30 minutes) downregulates the LPS-induced secretion and expression of HMGB1 in keratinocytes[1].
Lipoxin A4 (LXA4) inhibits the expression of IL-6 and IL-8 in NHEKs[2].
Lipoxin A4 downregulates the expression of cyclin D1[2].
Lipoxin A4 also suppresses the ERK1/2 phosphorylation and NF-kB-p65 nuclear translocation of NHEKs[2].
LXA4 (100 nM; preincubation for 30 minutes)inhibits the proliferation of NHEKs with or without stimulating by LPS (10 μg/mL)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lipoxin A4 Related Antibodies

Western Blot Analysis[1]

Cell Line: Normal human epidermal keratinocytes (NHEKs)
Concentration: 100 nM
Incubation Time: 30 minutes.
Result: HMGB1 protein levels in the cytoplasm of NHEKs were induced by LPS, which were decreased after preincubation with LXA4 but decreased in the nucleus after stimulation with LPS.

Cell Proliferation Assay[2]

Cell Line: Normal human epidermal keratinocytes (NHEKs)
Concentration: 100 nM
Incubation Time: 30 minutes
Result: A significant increase in proliferation of NHEKs after 7 days of stimulation with LPS (10 μg/mL) was seen. However, there was a significant decrease in the proliferation of NHEKs when pretreated with LXA4 for 30 min.
In Vivo

Lipoxin A4 (intrathecal injection; 10-100 ng; 3 days) potently alleviates radicular pain in a rat model of non-compressive lumbar disc herniation[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rat models of non-compressive lumbar disc herniation[4]
Dosage: 10 and 100 ng
Administration: Intrathecal injection; 3 days
Result: Alleviated the development of neuropathic pain.
Inhibited the upregulation of pro-inflammatory cytokines (TNF-a and IL-1β).
Upregulated the expression of anti-inflammatory cytokines (TGF-β1 and IL-10) and attenuated the activation of NF-κB/p65, p-ERK, p-JNK, but not p-p38.
Peso molecular

352.47

Fòrmula

C20H32O5
No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

CCCCC[C@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](O)CCCC(O)=O
Structure Classification
Initial Source
Envío

Shipping with dry ice.
Almacenamiento

Solution, -20°C, 1 year
Pureza y Documentación

Purity: 98.0%

SDS (544 KB)

COA (240 KB)

Instrucciones de manejo (2659 KB)
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lipoxin A4 Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lipoxin A489663-86-5LXA4Lipoxin A 4Lipoxin A-4LXA 4LXA-4Interleukin RelatedEndogenous MetaboliteILlipoxin A4,IL-6interleukin-6,IL-8interleukin-8,NHEKsepidermal keratinocytesLPSlipopolysaccharideERK1/2,NF-kBInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Lipoxin A4
Cat. No.:
HY-113509
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (544 KB) Français - FR (544 KB) Deutsch - DE (544 KB) Norwegian - NO (544 KB) Español - ES (544 KB) Swedish - SV (544 KB) Italian - IT (544 KB) Korean - KR (544 KB) Portuguese - PT (544 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.